期刊文献+

心房颤动60例抗凝治疗分析

The analysis of anticoagulant treatment to atrial fibrillation in 60 cases
下载PDF
导出
摘要 目的:对心房颤动60例患者抗凝治疗进行分析。方法:回顾性分析本院2007年2~10月住院患者中的心房颤动患者60例,分为心血管病房40例及其他病房20例两组,均采用华法林抗凝治疗。结果:60例患者经过治疗之后,有效51例(85%),无效9例(15%),有效率为85%。根据患者服用华法林后第3~4天INR值上升的速度和幅度,判断患者对华法林的敏感性,分为不敏感、敏感、很敏感,根据敏感性以1mg增减剂量,不敏感者加量1mg,很敏感者减量1mg。本组60例患者中很敏感者15例,平均体重为(49.85±8.06)kg;敏感者32例,平均体重为(58.97±6.58)kg;不敏感者13例,平均体重为(81.19±7.77)kg。体重小的人群敏感性高,体重大的人群敏感性低。结论:华法林价格便宜,抗凝效果肯定,只要掌握好其药理特性,还是目前最好的选择。 Objective:To 60 patients for anticoagulant therapy of atrial fibrillation were analyzed.Methods:A retrospective analysis of hospital 2 October 2007 hospitalized patients with atrial fibrillation in 60 patients,divided into 40 cases of cardiovascular wards and other wards in 20 cases the two groups were treated with warfarin.Results:60 patients after treat ment,effective in 51 cases(85%),9 cases(15%),the effective rate of 85%.According to the patients taking warfarin 3 to 4 days after the INR values have increased the speed and magnitude,to determine the sensitivity of warfarin in patients divided into non-sensitive,sensitive,very sensitive,according to increase or decrease the sensitivity to 1 mg dose,were not sensitive to dosage 1 mg,were very sensitive to reduction of 1 mg.The group of 60 patients,15 cases are sensitive to the average body weight(49.85±8.06) kg;sensitivity in 32 patients,average weight(58.97±6.58) kg;not sensitive to 13 patients,average weight(81.19±7.77) kg.Weight of small populations with high sensitivity and low weight of the sensitivity of a large crowd.Conclusion:Cheap warfarin,anticoagulant effects are,as long as the master of its pharmacological properties,or the best choice.
作者 甄彤
出处 《中国当代医药》 2010年第31期15-16,共2页 China Modern Medicine
关键词 心房颤动 抗凝治疗 分析 Atrial fibrillation Anticoagulant therapy Analysis
  • 相关文献

参考文献6

二级参考文献25

  • 1黄维义,严丽,彭永权,李刚,刘应才,莫余波,李家富,罗兴林.房颤患者抗凝治疗现状分析[J].中国医师进修杂志(内科版),2006,29(1):58-59. 被引量:13
  • 2黄维义,李刚,严丽,彭永权,罗兴林.华法林在慢性心房颤动抗凝治疗中的应用[J].临床心血管病杂志,2006,22(5):276-278. 被引量:24
  • 3Vertheugt FW. Stroke prevention in atria/fibrillation[J]. Neth J Med, 2006, 64(2) :31 - 33.
  • 4Hyiek EM, Skates ST, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patiens with nonrheumatic atrialfibrilliation[J ]. N Engl J Med, 1996, 335:540 - 546.
  • 5Lip GYH.Thromboprophylaxis for atrial fibrillation[J].Lancet,1999,353:426.
  • 6Yamaguchi T.Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation-a multicenter,prospective,randomized trial[J].Stroke,2000,31:817-821.
  • 7Petersen P,Grind M,Adler J.SPORTIF Ⅱ Investigators.Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.SPORTIFⅡ:A dose guiding,tolerability,and safety study[J].J Am Coll Cardiol,2003,41:1445-1451.
  • 8Executive Steering Committee on behalf of the SPORTIF Ⅲ investigators.Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF Ⅲ):Randomized controlled trial[J].Lancet,2003,362:1691-1698.
  • 9Halperin JL,and the Executive Steering Committee,on behalf of the SPORTIF Ⅲ and Ⅴ Study Investigators.Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation:rationale,objectives,and design of a pair of clinical studies and baseline patient characteristics (SPORTIF Ⅲ and V)[J].Am Heart J,2003,146:431-438.
  • 10The Stroke Prevention in A trial Fibrillation Investigators.Stroke prevention in atrial fibrillation study:Final results[J].Circulation,1991,84:527-539.

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部